BioNTech SE (BNTX) Monday announced a sharp fall in third-quarter earnings compared to the prior year, as the commercial revenues were down sharply. The company revised down its COVID-19 vaccine revenues for the full year 2023.
BioNTech SE (BNTX) shares are adding more than 4 percent on Tuesday morning trade after the company reported positive data for its first-in-human Phase 1/2 trial of Claudin-6, CAR-T cell therapy candidate BNT211 in patients with CLDN6-positive refractory/relapsed solid tumors.
MAINZ, Germany, October 23, 2023 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the.
Program updates include new data for investigational CAR-T and ex-vivo T cell therapies, a novel ADC, a FixVac off-the-shelf mRNA cancer vaccine, and a.